Genmab (GMAB)
(Real Time Quote from BATS)
$28.01 USD
-0.07 (-0.25%)
Updated Sep 18, 2025 01:26 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GMAB 28.01 -0.07(-0.25%)
Will GMAB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
Other News for GMAB
GMAB's price falls by 0.57% on September 17, though its technical setup remains stable.
GMAB forms NR7 on September 16
GMAB forms Pocket Pivot on September 15
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
Is GMAB likely to continue higher? Slingshot Bullish shows up after slipping 2.76%